Truist Financial Lowers Community Health Systems Price Target

Research analysts cut their price objective on the healthcare company's stock.

Apr. 13, 2026 at 5:27pm

An extreme close-up of intricate, heavy industrial banking machinery and equipment, conveying a sense of institutional financial power and security without using any literal currency or financial symbols.Truist Financial's lowered price target on Community Health Systems stock reflects ongoing challenges in the hospital industry.Franklin Today

Truist Financial analysts lowered their price target on shares of Community Health Systems (NYSE: CYH) from $4.00 to $3.50 and maintained a 'hold' rating on the stock. Other research firms have also recently weighed in on CYH, with some upgrading the stock to 'strong buy' while others have downgraded it to 'sell'.

Why it matters

This price target reduction by a major financial institution signals continued uncertainty around Community Health Systems' outlook, as the healthcare provider navigates a challenging operating environment for hospitals and healthcare systems.

The details

In a research report, Truist Financial analysts cited the company's ongoing struggles, lowering their price objective from $4.00 to $3.50 per share while keeping a 'hold' rating. Other firms have taken varying stances, with Zacks Research upgrading CYH to 'strong buy' and Weiss Ratings downgrading it to 'sell'.

  • The Truist Financial report was issued on Monday, April 13, 2026.

The players

Truist Financial

A major U.S. financial services company that provides banking, investing, insurance, and mortgage products and services.

Community Health Systems

One of the largest publicly traded hospital operators in the United States, owning, leasing, and managing general acute care hospitals and outpatient facilities, primarily in non-urban and mid-market communities.

Got photos? Submit your photos here. ›

The takeaway

This price target reduction by Truist Financial reflects the ongoing challenges facing Community Health Systems as it navigates a complex healthcare landscape. The mixed analyst views on the stock underscore the uncertainty surrounding the company's future performance and growth prospects.